Table 2.

Selected parameters for estimating cost-effectiveness of HPV vaccination using the PRIME model

No	Parameter	Average value/value	Range	Source
1	Vaccine delivery cost per FIG	$ 10.4	$ 9.5-$ 11.3	Costing study
2	Cancer treatment cost			Costing study
	Scenario 5 (IA1 - IIB proximal treated by Radical hysterectomy)	$ 368.3	N/A
	Scenario 6 (IA1 - IIB proximal treated by Radical hysterectomy + Chemoradiation)	$ 8700.1	N/A
	Scenario 7 (IA1 - IIB proximal treated by Radical hysterectomy + Radio therapy (Intr))	$ 2209.6	N/A
	Scenario 8 (IA1 - IIB proximal treated by Radical hysterectomy + Radio-therapy (External beam))	$ 1449.9	N/A
	Scenario 9 (IIB distant – IVB treated by Chemoradiation)	$ 11448.1	N/A
	Scenario 10 (IIB distant – IVB treated by Radio therapy (Intra + External))	$ 5166.52	N/A
	Scenario 11 (average cost of all scenarios)	$ 4,890.44	N/A
3	DALYs lost per non-fatal cancer episode	0.7		Literature review
4	DALYs lost per fatal cancer episode (excluding life years lost)	0.8		Literature review
5	Epidemiological data			Literature review
	Cervical cancer incidence in 2012	6.1 per 100000		GLOBOCAN 2012
		20.5 per 100000
		26.7 per 100000
		31.3 per 100000
		32.1 per 100000
		26.2 per 100000
		20.5 per 100000
		13 per 100000
	Cervical cancer mortality in 2012	1.1 per 100000		GLOBOCAN 2012
		6.5 per 100000
		15.1 per 100000
		18.8 per 100000
		21.3 per 100000
		21.8 per 100000
		20 per 100000
		16.1 per 100000
		5.3 per 100000
	All-cause mortality in 2012	100 - 52 800 per 100 000 (depending on age)		National statistics